RU2004106569A - Способ применения антибиотиков - Google Patents
Способ применения антибиотиков Download PDFInfo
- Publication number
- RU2004106569A RU2004106569A RU2004106569/14A RU2004106569A RU2004106569A RU 2004106569 A RU2004106569 A RU 2004106569A RU 2004106569/14 A RU2004106569/14 A RU 2004106569/14A RU 2004106569 A RU2004106569 A RU 2004106569A RU 2004106569 A RU2004106569 A RU 2004106569A
- Authority
- RU
- Russia
- Prior art keywords
- dose
- daptomycin
- administering
- administered
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Claims (27)
1. Способ лечения бактериальной инфекции у человека, нуждающегося в таком лечении, включающий в себя введение даптомицина с такими интервалами между приемами лекарственных доз, при которых минимизируется токсичность в отношении скелетных мышц, включающий в себя стадию введения терапевтически эффективного количества даптомицина в дозе от 3 до 75 мг/кг, при котором даптомицин вводят многократно в интервале от одного раза каждые 48 ч до одного раза в неделю.
2. Способ по п. 1, при котором указанное введение представляет собой пероральное, подкожное или внутривенное введение.
3. Способ по п.2, при котором доза составляет от 4 до 12 мг/кг.
4. Способ по п.3, при котором доза составляет 4 мг/кг.
5. Способ по п.2, при котором доза составляет 10, 11, 12, 13, 14, 15, 16, 20 или 25 мг/кг.
6. Способ по п.3, при котором доза составляет 6 мг/кг.
7. Способ по п.3, при котором доза составляет 8 мг/кг.
8. Способ по п.2, при котором дозу даптомицина вводят повторно, причем интервал введения составляет от одного раза каждые 48 ч до одного раза в неделю.
9. Способ по п.8, при котором интервал дозирования соответствует одному введению каждые 72 ч.
10. Способ по п.8, при котором интервал дозирования соответствует одному введению каждые 96 ч.
11. Способ по п.8, при котором доза составляет от 4 до 12 мг/кг.
12. Способ по п.11, при котором доза составляет 4 мг/кг.
13. Способ по п.11, при котором доза составляет 6 мг/кг.
14. Способ по п.11, при котором доза составляет 8 мг/кг.
15. Способ по п.8, при котором доза составляет от 25 до 75 мг/кг.
16. Способ по п.8, при котором доза составляет от 10 до 25 мг/кг.
17. Способ по п.8, при котором даптомицин вводят в течение периода от 3 дней до 6 месяцев.
18. Способ по п.8, при котором даптомицин вводят в течение от 7 до 28 дней.
19. Способ по п.8, при котором даптомицин вводят в течение от 7 до 14 дней.
20. Способ по п.8, при котором при котором интервал дозирования соответствует одному введению каждые 48 часов.
21. Способ по п.20, при котором доза составляет от 4 до 12 мг/кг.
22. Способ по п.21, при котором доза составляет 4 мг/кг.
23. Способ по п.21, при котором доза составляет 6 мг/кг.
24. Способ по п.21, при котором доза составляет 8 мг/кг.
25. Способ по п.20, при котором даптомицин вводят в течение периода от 3 дней до 6 месяцев.
26. Способ по п.20, при котором даптомицин вводят в течение от 7 до 28 дней.
27. Способ по п.20, при котором даптомицин вводят в течение от 7 до 14 дней.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10182898P | 1998-09-25 | 1998-09-25 | |
| US60/101,828 | 1998-09-25 | ||
| US12575099P | 1999-03-24 | 1999-03-24 | |
| US60/125,750 | 1999-03-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001111327/14A Division RU2232592C2 (ru) | 1998-09-25 | 1999-09-24 | Способ лечения бактериальной инфекции |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2004106569A true RU2004106569A (ru) | 2005-08-10 |
| RU2363489C2 RU2363489C2 (ru) | 2009-08-10 |
| RU2363489C9 RU2363489C9 (ru) | 2010-03-20 |
Family
ID=26798675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004106569/14A RU2363489C9 (ru) | 1998-09-25 | 2004-03-04 | Способ применения антибиотиков |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6468967B1 (ru) |
| EP (2) | EP1674107B8 (ru) |
| JP (4) | JP4184607B2 (ru) |
| KR (2) | KR20010075327A (ru) |
| CN (2) | CN1150029C (ru) |
| AT (1) | ATE322280T1 (ru) |
| AU (1) | AU764348B2 (ru) |
| BR (1) | BR9914051A (ru) |
| CA (1) | CA2344318C (ru) |
| CY (3) | CY1105556T1 (ru) |
| DE (3) | DE122006000049I1 (ru) |
| DK (2) | DK1674107T3 (ru) |
| ES (2) | ES2603086T3 (ru) |
| HK (1) | HK1040363B (ru) |
| HU (1) | HU230656B1 (ru) |
| IS (2) | IS5890A (ru) |
| LU (1) | LU91254I2 (ru) |
| NL (1) | NL300232I2 (ru) |
| NO (1) | NO20011454L (ru) |
| NZ (1) | NZ510690A (ru) |
| PL (2) | PL206091B1 (ru) |
| PT (2) | PT1115417E (ru) |
| RU (1) | RU2363489C9 (ru) |
| SI (2) | SI1115417T1 (ru) |
| TR (1) | TR200100841T2 (ru) |
| WO (1) | WO2000018419A2 (ru) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1674107T3 (en) | 1998-09-25 | 2016-12-19 | Cubist Pharmaceuticals Llc | Use of daptomycin |
| CN1425025A (zh) | 1999-12-15 | 2003-06-18 | 卡比斯特制药公司 | 作为抗菌剂的新颖的脂肽 |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| NZ571597A (en) | 2000-12-18 | 2010-05-28 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides |
| US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| EP1932853A1 (en) | 2001-08-06 | 2008-06-18 | Cubist Pharmaceutical Inc. | Novel depsipeptides and process for preparing same |
| US20040147441A1 (en) * | 2002-08-23 | 2004-07-29 | Leach Timothy S. | Methods and reagents for preventing bacteremias |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050277581A1 (en) * | 2002-11-18 | 2005-12-15 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20050220862A1 (en) | 2004-03-31 | 2005-10-06 | Bernstein Joel E | Compositions with reduced hepatotoxicity |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| US20080051326A1 (en) * | 2004-11-12 | 2008-02-28 | Alexander Dylan C | Antiinfective Lipopeptides |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070238630A1 (en) * | 2006-03-29 | 2007-10-11 | Phillips Douglas H | Subcutaneous skin cleanser |
| EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| TW200940552A (en) * | 2008-03-04 | 2009-10-01 | Elan Pharm Inc | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| EP2320933B1 (en) | 2008-07-17 | 2017-12-27 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
| US8815838B2 (en) | 2008-10-07 | 2014-08-26 | David C. Griffith | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| PL2346509T3 (pl) | 2008-10-07 | 2021-03-08 | Horizon Orphan Llc | Lewofloksacyna w postaci aerozolu dla zmniejszania stanu zapalnego płuc |
| US8809263B2 (en) * | 2008-10-24 | 2014-08-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Anti-infective hydroxy-phenyl-benzoates and methods of use |
| EP2379580B1 (en) | 2008-12-22 | 2013-10-23 | Cubist Pharmaceuticals, Inc. | Novel antibacterial agents for the treatment of gram positive infections |
| US8343912B2 (en) | 2008-12-23 | 2013-01-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2011008193A1 (en) * | 2009-07-13 | 2011-01-20 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| US8450300B2 (en) * | 2009-07-13 | 2013-05-28 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| MX353288B (es) | 2009-09-04 | 2018-01-08 | Raptor Pharmaceuticals Inc | Uso de levofloxacina aerosolizada para el tratamiento de fibrosis quistica. |
| JP6041673B2 (ja) | 2009-11-23 | 2016-12-14 | キュービスト ファーマシューティカルズ リミテッド ライアビリティ カンパニー | リポペプチド組成物および関連する方法 |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| US8461188B2 (en) | 2011-10-20 | 2013-06-11 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| MX366122B (es) * | 2012-09-11 | 2019-06-27 | Hospira Australia Pty Ltd | Formulaciones de daptomicina y usos de la misma. |
| CN103006562B (zh) * | 2013-01-21 | 2014-09-17 | 西南大学 | 达托霉素醇质体制剂 |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| CN109310735A (zh) * | 2016-05-13 | 2019-02-05 | 我希望增效剂公司 | 新阳离子肽spr741对抗生素活性的增效作用 |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| FR2755857B1 (fr) * | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
| FR2772272B1 (fr) * | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
| DK1674107T3 (en) | 1998-09-25 | 2016-12-19 | Cubist Pharmaceuticals Llc | Use of daptomycin |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
-
1999
- 1999-09-24 DK DK06006697.4T patent/DK1674107T3/en active
- 1999-09-24 EP EP06006697.4A patent/EP1674107B8/en not_active Expired - Lifetime
- 1999-09-24 ES ES06006697.4T patent/ES2603086T3/es not_active Expired - Lifetime
- 1999-09-24 PT PT99949913T patent/PT1115417E/pt unknown
- 1999-09-24 WO PCT/US1999/022366 patent/WO2000018419A2/en active IP Right Grant
- 1999-09-24 EP EP99949913A patent/EP1115417B1/en not_active Revoked
- 1999-09-24 TR TR2001/00841T patent/TR200100841T2/xx unknown
- 1999-09-24 DE DE1999630758 patent/DE122006000049I1/de active Pending
- 1999-09-24 HU HU0103874A patent/HU230656B1/hu unknown
- 1999-09-24 DE DE200612000049 patent/DE122006000049I2/de active Active
- 1999-09-24 ES ES99949913T patent/ES2259845T3/es not_active Expired - Lifetime
- 1999-09-24 DK DK99949913T patent/DK1115417T3/da active
- 1999-09-24 AU AU62687/99A patent/AU764348B2/en not_active Expired
- 1999-09-24 US US09/406,568 patent/US6468967B1/en not_active Expired - Lifetime
- 1999-09-24 KR KR1020017003735A patent/KR20010075327A/ko not_active Application Discontinuation
- 1999-09-24 CN CNB998124982A patent/CN1150029C/zh not_active Ceased
- 1999-09-24 SI SI9930904T patent/SI1115417T1/sl unknown
- 1999-09-24 PT PT60066974T patent/PT1674107T/pt unknown
- 1999-09-24 JP JP2000571937A patent/JP4184607B2/ja not_active Expired - Lifetime
- 1999-09-24 AT AT99949913T patent/ATE322280T1/de active
- 1999-09-24 NZ NZ510690A patent/NZ510690A/xx not_active IP Right Cessation
- 1999-09-24 KR KR1020107006807A patent/KR20100051735A/ko not_active Application Discontinuation
- 1999-09-24 DE DE69930758T patent/DE69930758T2/de not_active Expired - Lifetime
- 1999-09-24 CA CA002344318A patent/CA2344318C/en not_active Expired - Lifetime
- 1999-09-24 CN CNA200410031708XA patent/CN1530136A/zh active Pending
- 1999-09-24 PL PL384274A patent/PL206091B1/pl unknown
- 1999-09-24 SI SI9931082A patent/SI1674107T1/sl unknown
- 1999-09-24 PL PL348328A patent/PL203689B1/pl unknown
- 1999-09-24 BR BR9914051-9A patent/BR9914051A/pt not_active Application Discontinuation
-
2001
- 2001-03-14 IS IS5890A patent/IS5890A/is unknown
- 2001-03-22 NO NO20011454A patent/NO20011454L/no not_active Application Discontinuation
-
2002
- 2002-01-09 HK HK02100152.2A patent/HK1040363B/zh not_active IP Right Cessation
- 2002-02-20 US US10/082,544 patent/US6852689B2/en not_active Expired - Lifetime
-
2003
- 2003-05-27 JP JP2003149968A patent/JP2003321389A/ja not_active Withdrawn
-
2004
- 2004-03-04 RU RU2004106569/14A patent/RU2363489C9/ru active
- 2004-08-17 JP JP2004237765A patent/JP2004339238A/ja not_active Withdrawn
-
2006
- 2006-04-18 CY CY20061100536T patent/CY1105556T1/el unknown
- 2006-06-23 NL NL300232C patent/NL300232I2/nl unknown
- 2006-06-28 LU LU91254C patent/LU91254I2/fr unknown
- 2006-07-18 CY CY200600003C patent/CY2006003I1/el unknown
- 2006-09-22 JP JP2006258107A patent/JP2006335773A/ja not_active Withdrawn
-
2009
- 2009-03-10 IS IS8807A patent/IS8807A/is unknown
-
2016
- 2016-11-24 CY CY20161101219T patent/CY1118334T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004106569A (ru) | Способ применения антибиотиков | |
| DK1201246T3 (da) | Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni | |
| KR910019618A (ko) | 발기부전증 치료용 제약 조성물 | |
| WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| RU2003125274A (ru) | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| WO2002064214A3 (en) | Anti cancer combination of substituted pyrroles and paclitaxel | |
| KR960703593A (ko) | (R)-암로디핀에 의한 평활근 세포 이동의 억제 (Inhibition of Smooth Muscle Cell Migration by (R)-Amlodipine) | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| KR930702985A (ko) | 식도암의 치료 | |
| KR930702983A (ko) | 난소암의 치료 | |
| CA2368184A1 (en) | Method and means for treating post-polio syndrome | |
| UA30251A (ru) | Способ лечения гипертонии сфинктера одди у больных хроническим безкаменным холециститом при сочетании с повышением тонуса симпатической нервной системы | |
| TH50700A (th) | วิธีการและสารผสมสำหรับรักษาความเจ็บปวด | |
| RU98109932A (ru) | Применение 1-(2-нафт-2-илэтил)-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина для получения лекарственных средств, предназначенных для лечения бокового амиотрафического склероза | |
| TH50374A (th) | วิธีการสำหรับการป้องกันโรคอุจจาระร่วง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification | ||
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20160229 |
|
| PD4A | Correction of name of patent owner | ||
| PD4A | Correction of name of patent owner |